EDAP and Telix Sign Letter of Intent to Integrate Robotic HIFU with PSMA PET
EDAP TMS signed a letter of intent with Telix Pharmaceuticals to jointly research integration of Focal One Robotic HIFU with PSMA PET imaging for primary and salvage prostate cancer treatments. Based on positive HIFI-2 outcomes, the collaboration aims to improve patient outcomes by integrating PSMA PET scans within the HIFU treatment workflow.
1. Collaboration Details
EDAP TMS S.A. has entered into a letter of intent with Telix Pharmaceuticals to explore joint clinical research activities and physician education focused on combining EDAP’s Focal One Robotic HIFU platform with Telix’s PSMA PET imaging products in prostate cancer management.
2. Investigational Focus
Initial research will study the integration of PSMA PET diagnostic scans within the Focal One workflow to optimize treatment planning, deliver precise image-guided focal therapy, and monitor responses both in the primary treatment setting and as salvage therapy after radiation.
3. Clinical Rationale
This collaboration builds on early clinical experience and positive results from the prospective HIFI-2 study demonstrating effective Focal One treatment for patients with recurrence after radiation, with the goal of further personalizing focal therapy strategies and improving patient outcomes.
4. Financial and Operational Impact
The letter of intent imposes no financial commitments on either party and is not expected to have a material impact on EDAP’s financial results; the parties may pursue definitive agreements and joint educational programs in the future.